enGene’s (ENGN) “Market Perform” Rating Reiterated at Citizens Jmp

Citizens Jmp reaffirmed their market perform rating on shares of enGene (NASDAQ:ENGN) in a report published on Wednesday,Benzinga reports.

A number of other brokerages have also weighed in on ENGN. Morgan Stanley lowered shares of enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price target on the stock. in a report on Thursday, June 18th. Wall Street Zen upgraded enGene from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Citigroup reaffirmed a “market perform” rating on shares of enGene in a research report on Wednesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of enGene in a report on Wednesday, August 12th. Finally, HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of enGene in a research report on Tuesday. Four equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $11.05.

enGene Stock Up 1.7%

ENGN opened at $1.80 on Wednesday. enGene has a 12 month low of $1.40 and a 12 month high of $12.25. The business has a 50-day moving average of $1.83 and a two-hundred day moving average of $3.92. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.21 and a quick ratio of 12.57. The stock has a market capitalization of $120.58 million, a price-to-earnings ratio of -1.59 and a beta of -0.28.

enGene (NASDAQ:ENGN) last announced its quarterly earnings data on Tuesday, September 8th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.04). On average, research analysts expect that enGene will post -1.81 earnings per share for the current year.

Institutional Investors Weigh In On enGene

Institutional investors have recently bought and sold shares of the business. SR One Capital Management LP acquired a new stake in shares of enGene in the second quarter worth $1,293,607. Eversept Partners LP increased its holdings in enGene by 12.0% in the 1st quarter. Eversept Partners LP now owns 510,543 shares of the company’s stock valued at $3,477,000 after purchasing an additional 54,708 shares in the last quarter. Renaissance Technologies LLC increased its holdings in enGene by 651.1% in the 1st quarter. Renaissance Technologies LLC now owns 156,100 shares of the company’s stock valued at $1,063,000 after purchasing an additional 135,318 shares in the last quarter. Siren L.L.C. raised its position in enGene by 57.5% in the first quarter. Siren L.L.C. now owns 5,253,159 shares of the company’s stock valued at $35,774,000 after purchasing an additional 1,916,895 shares during the period. Finally, Sei Investments Co. purchased a new position in enGene in the first quarter valued at about $409,000. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

Key enGene News

Here are the key news stories impacting enGene this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $4.00 price target, substantially above the recent trading level. The firm modestly improved its EPS forecasts across Q4 2026 through FY2029, including reducing its projected FY2026 loss to $1.89 per share from $1.95 and its FY2029 loss to $0.76 from $0.77. These revisions suggest slightly better anticipated financial performance, although enGene is still expected to remain unprofitable.
• Positive Sentiment: A Seeking Alpha analysis highlighted enGene’s cash position of approximately $3.97 per share and cost reductions, including a roughly 50% workforce reduction. Management expects these measures to extend the cash runway into 2029, potentially supporting operations through important regulatory milestones. enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market
• Neutral Sentiment: Citizens JMP reaffirmed a Market Perform rating, indicating limited near-term conviction despite the potential upside cited by HC Wainwright. Citizens JMP Reaffirms Market Perform Rating for enGene
• Neutral Sentiment: Reported short interest was zero shares, offering no meaningful evidence of either short-selling pressure or a potential short-covering catalyst.
• Negative Sentiment: enGene’s lead asset, detalimogene voraplasmid, faces FDA approval risk because of weak 12-month durability data. Management is pursuing a surfactant cohort to improve efficacy, but the outcome remains uncertain. The company also recently reported a quarterly EPS loss wider than analysts expected, reinforcing its speculative risk profile.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.